(4R)-4-甲基-4-[2-(1-甲基吡咯-2-基)乙烯基]-1,3-恶唑烷-2-酮 | 566938-11-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 中文名称: (4R)-4-甲基-4-[2-(1-甲基吡咯-2-基)乙烯基]-1,3-恶唑烷-2-酮
• 英文名称: (4R)-methyl-4-[2-(1-methylpyrrol-2-yl)ethenyl]-1,3-oxazolidin-2-one
• 英文别名: (4R)-4-methyl-4-[2-(1-methylpyrrol-2-yl)ethenyl]-1,3-oxazolidin-2-one
• CAS: 566938-11-2
• 化学式: C₁₁H₁₄N₂O₂
• 分子量: 206.244
• InChiKey: BIZRCKJCJHHXEC-LLVKDONJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  43.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (4R)-4-甲基-4-[2-(1-甲基吡咯-2-基)乙烯基]-1,3-恶唑烷-2-酮 在 palladium 10% on activated carbon 氢气 作用下， 以 甲醇 为溶剂， 反应 1.0h， 以88%的产率得到(4R)-4-甲基-4-[2-(1-甲基吡咯-2-基)乙基]-1,3-恶唑烷-2-酮
  参考文献：
  名称：

  EP1733724

  摘要：

  公开号：
• 作为产物：
  描述：

  (1,3-二羟基-2-甲基-2-丙基)(2-甲基-2-丙基)氨基甲酸 在 sodium hydroxide 、 4 A molecular sieve 、 TOYOBO 、 potassium tert-butylate 、 pyridinium chlorochromate 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 异丙醚 、 水 为溶剂， 反应 8.33h， 生成 (4R)-4-甲基-4-[2-(1-甲基吡咯-2-基)乙烯基]-1,3-恶唑烷-2-酮
  参考文献：
  名称：

  Asymmetric synthesis of α,α-disubstituted α-amino alcohol derivatives

  摘要：

  We herein report an asymmetric synthesis of alpha,alpha-disubstituted alpha-amino alcohol derivatives 3, key intermediates of a novel immunomodulator, using enzymatic desymmetrization of 2-alkyl-2-tert-butoxycarbonylamino-1,3-propanediols 1a and 1b. This method makes it possible to prepare a chiral analogue of FTY720 4. These synthetic procedures allow for a broad structure variation in order to evaluate structure-activity relationships and the mechanism of action for sphingosine 1-phosphate-1 (SIP1) receptor agonist. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetasy.2006.10.007

文献信息

• Amino alcohol compound
  申请人：Nishi Takahide

  公开号：US20070191468A1

  公开（公告）日：2007-08-16

  A pharmaceutical composition is provided that has a low toxicity, demonstrates superior physicochemical properties and pharmacokinetics, and has superior peripheral blood lymphocyte count lowering activity. The pharmaceutical composition contains a compound having general formula (I): [Chemical Formula 1] (wherein R 1 represents a methyl group or an ethyl group, R 2 represents a methyl group or an ethyl group, and R 3 represents a phenyl group substituted with 1 to 3 substituents selected from the group consisting of a halogen atom, a lower alkyl group, a cycloalkyl group, a lower alkoxy group, a halogeno lower alkyl group, a lower aliphatic acyl group and a cyano group), a pharmacologically acceptable salt thereof or a pharmacologically acceptable ester thereof.

  提供了一种低毒性、表现出优越的物理化学性质和药代动力学，并具有优越的外周血淋巴细胞计数降低活性的药物组合物。该药物组合物包含具有一般式（I）的化合物：[化学式1]（其中R1代表甲基基团或乙基基团，R2代表甲基基团或乙基基团，R3代表苯基，该苯基被1至3个取自卤原子、较低烷基基团、环烷基团、较低烷氧基团、卤代较低烷基基团、较低脂肪酰基基团和氰基的取代基所取代），以及其药理学上可接受的盐或药理学上可接受的酯。
• Method for suppressing the number of peripheral blood lymphocytes using an amino alcohol compound
  申请人：Sankyo Company, Limited

  公开号：US07910617B2

  公开（公告）日：2011-03-22

  A method for suppressing the number of peripheral blood lymphocytes involving administering to a human in need thereof a pharmaceutically effective amount of a compound which is (2R) -2-amino-2-methyl-4-1-methyl-5-[4-(4-methylphenyl)butanoyl]pyrrol-2-yl}butan-1-ol or a pharmacologically acceptable salt thereof, such as the hydrochloride salt.

  一种抑制外周血淋巴细胞数量的方法，涉及向需要的人体内给予一种药物有效量的化合物，该化合物为（2R）-2-氨基-2-甲基-4-1-甲基-5-[4-(4-甲基苯基)丁酰基]吡咯-2-基}丁-1-醇或其药理学上可接受的盐，如盐酸盐。
• EP1733724
  申请人：——

  公开号：——

  公开（公告）日：——
• Asymmetric synthesis of α,α-disubstituted α-amino alcohol derivatives
  作者：Tsuyoshi Nakamura、Takashi Tsuji、Yukiko Iio、Shojiro Miyazaki、Toshiyasu Takemoto、Takahide Nishi

  DOI：10.1016/j.tetasy.2006.10.007

  日期：2006.10

  We herein report an asymmetric synthesis of alpha,alpha-disubstituted alpha-amino alcohol derivatives 3, key intermediates of a novel immunomodulator, using enzymatic desymmetrization of 2-alkyl-2-tert-butoxycarbonylamino-1,3-propanediols 1a and 1b. This method makes it possible to prepare a chiral analogue of FTY720 4. These synthetic procedures allow for a broad structure variation in order to evaluate structure-activity relationships and the mechanism of action for sphingosine 1-phosphate-1 (SIP1) receptor agonist. (c) 2006 Elsevier Ltd. All rights reserved.